Business Wire

After Three Successful Years With the IBSA Class40 and Skipper Alberto Bona, IBSA’s Sports Project Comes to an End

Share

Three years of intense work, 25,000 miles of racing, five Atlantic crossings, ten regattas, a first and a fourth place in the international Class40 circuit, five podium finishes and two victories: a remarkable human and sporting achievement that combined tenacity, courage, adventure, sustainability and inclusion. This marks the conclusion, after three sporting seasons, of the project that united the multinational pharmaceutical company IBSA with ocean sailor Alberto Bona. An intense journey that began in 2022 with the construction of the Class40 IBSA in France and touched the shores of Brittany, Normandy, England, Ireland, Martinique and Guadeloupe, the United States and Canada.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241127852350/en/

“We experienced three intense years, during which we took the IBSA brand around the world; a sporting project that allowed ingenuity, courage, perseverance and passion to fully manifest”, announced Arturo Licenziati, President and CEO of IBSA.It’s been an extraordinary and highly formative journey, capable of narrating and promoting our values alongside Alberto Bona and his team, led by Luca Bertacchi. Thanks to the extraordinary skills of our skipper, we were able to transform a sporting challenge into a symbol of innovation, sustainability and mutual growth”.

The Sailing into the Future. Together journey began in La Trinité-sur-Mer in February 2022, with the construction of the Class40 IBSA, designed by Sam Manuard. The first race, the Route du Rhum, started on November 9, 2022, a few weeks after the boat’s launch, and ended with an excellent finish in the top ten. The 2023 season crowned the success of the Class40 IBSA and Alberto Bona, with the achievement of the 24-hour speed record aboard a Class40, two first-place finishes, several podiums and victory in the International Class Championship, traditionally dominated by French sailors. The 2023 season was marked by collaborations with talented skippers, including Spaniard Pablo Santurde del Arco, with whom Bona shared the majority of the races, and the exceptional Italian sailor Francesca Clapcich. 2024 was the year of the project’s maturity: Alberto returned to solo sailing across the Atlantic in the Transat CIC from Lorient to New York, followed by a return to Europe along the northern route of the Québec Saint-Malo. The season finally ended with a third-place finish at the Normandy Channel Race, in crew with Italian skipper Alberto Riva.

"It has been a very demanding three years: all the people involved in the challenge, with great courage, had to do their best and go beyond their limits to achieve their objectives" – stated skipper Alberto Bona. "I would like to thank Dr. Arturo Licenziati – who believed in us – and the entire IBSA team, who carried forward his vision, enabling us to achieve great results. A heartfelt thank you to my entire team, in particular to our Team Manager Luca Bertacchi, promoter of the initiative and fellow adventurer, with whom I studied and shared every detail of this fantastic ocean sailing campaign".

Bona’s oceanic venture allowed IBSA to gain an in-depth understanding of the world of sailing. Thanks to Sailing into the Future. Together, an important inclusive sailing project for people with disabilities was launched, which will continue in the coming years, in collaboration with the Italian Sailing Federation and numerous sailing clubs in Italy, Switzerland, France, Spain and the USA.

“Alberto Bona showed us how sailing can be a way to discover oneself, test one’s skills and find inner strength to face any challenge. We will apply these principles to the world of inclusive sailing, so that this discipline can give everyone the chance to believe in their abilities, discover their talents and overcome obstacles. Indeed, inclusive sailing initiatives have the great merit of enriching the entire community by promoting a culture of acceptance and respect. This will be our focus in the coming sporting seasons”, concluded Giorgio Pisani, Vice President of IBSA and Project Leader.

THE PROJECT: The three-year project Sailing into the Future. Together was launched in January 2022. The partnership between IBSA and skipper Alberto Bona was born on common bases and values, and aims to use sailing as a corporate communication vehicle towards the market and the nautical world. Ingenuity, courage, innovation, responsibility are elements that unites IBSA and Alberto, and the oceanic challenge, in addition to the sporting competition, also metaphorically represents the company’s history, philosophy and vision, which are always oriented towards and are part of a path that brings IBSA increasingly closer to the topic of environmental and social sustainability, with a particular focus on inclusive sailing projects for people with disabilities. In November 2022, the Route du Rhum was the first sporting stage of the project Sailing into the Future. Together. In 2023, Bona and the Class40 IBSA participated in six regattas, including the Rolex Fastnet Race and the Transat Jacques Vabre. With two victories and three podiums, the record for the highest number of miles covered in 24 hours and over 15,000 miles sailed, Bona won first place overall in the Class40 International Championship. In 2024, between April and July, he will face two of the toughest transatlantic races on the international scene: the Transat CIC from Lorient (France) to New York and theQuebec Saint-Malo (from Canada to France).

THE SKIPPER: Alberto Bona is from Turin, and has a degree in philosophy. As a university student, he won the Panerai trophy aboard Stormvogel, fast ULDB and historic boat with which he crossed the Atlantic Ocean for the first time, winning the ARC with a New Zealand crew. In 2012 he took part in the Minitransat, finishing 5th, one of the best Italian results ever in this category. In 2015, he switched to the prototype category Mini 6.50 with Promostudi La Spezia: he won the Italian championship and finished second in the ocean crossing Les Sables-Azores. In 2017 he discovered the Class40: on Giovanni Soldini’s former Telecom Italia,he participated in the Transat Jacques Vabre, where he was forced to withdraw when he was in sixth place. In 2019 he was aboard the Maserati Multi 70 trimaran, one of the world’s fastest boats, where he practiced on the foils before moving on to the Figaro Beneteau 3, aboard which he participated in the Solitaire; the only Italian registered, in 2020 he finished 7th among the rookies in the first year and 16th overall. In 2021 he won the Italian offshore team title and the Europeans in mixed doubles aboard the Figaro 3. In 2022 he started the new project in partnership with IBSA: after an eighth place in the Route du Rhum 2022, in 2023 Alberto won the Class40 International Championship, closing a season with three podiums and over 15,000 miles covered.

THE BOAT: Designed by French naval architect Sam Manuard and built by the JPS Production shipyard, Alberto Bona’s boat is a Class40 Mach 5 model. Its main characteristics are: scow bow – rounded and with a wider and flatter shape than standard bows – designed to stay high above the water and avoid being submerged; all-round hull, particularly performing in conditions of strong tailwinds; and a large, shielded cockpit, to face extreme conditions of navigation in as comfortable and safe as possible positions.

IBSA: IBSA (Institut Biochimique SA) is a Swiss multinational pharmaceutical Company, founded in 1945 in Lugano. Today, its products are present in over 90 countries on 5 continents, through the Company’s 20 subsidiaries located in Europe, China, and the United States. The company has a consolidated turnover of 986 million CHF, and employs over 2,300 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents, plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241127852350/en/

Contacts

For more information, visit www.ibsasailing.com/en/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ibsasailing
.com%2Fen%2F&esheet=54158792&newsitemid=20241127852350&lan=en-US&anchor=www.ibsa
sailing.com%2Fen%2F&index=1&md5=af539247a6cd6fa497c4c1dcac07edb9

FOR PRESS INFORMATION
Francesca Capodanno – francesca.capodanno@wordpower.srl – mob: +39 349 881 0482
Benedetta Salemme – benedetta.salemme@noesis.net – mob. +39 324 800 7570

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable

GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release

Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus

Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release

Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye